Posts

AWT-020 by Anwita Biosciences for Sarcomas: Likelihood ...

AWT-020 is under clinical development by Anwita Biosciences and currently in Pha...

STAT+: The clock is ticking, and Cytokinetics is runnin...

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Health data breaches hit an all-time high in 2023

At least 116 million individuals were impacted by large and numerous health data...

STAT+: BioMarin appeases an activist

Want to stay on top of the science and politics driving biotech today? Sign up t...

Unraveling the mystery of hereditary diffuse gastric ca...

Gastric cancer, a significant global health burden, claims over 7% of cancer-rel...

Electronic “soil” enhances crop growth

Barley seedlings grow on average 50% more when their root system is stimulated e...

Devimistat by Cornerstone Pharmaceuticals for Soft Tiss...

Devimistat is under clinical development by Cornerstone Pharmaceuticals and curr...

(Nanatinostat + valganciclovir) by Viracta Therapeutics...

(Nanatinostat + valganciclovir) is under clinical development by Viracta Therape...

Enzalutamide by Pfizer for Fallopian Tube Cancer: Likel...

Enzalutamide is under clinical development by Pfizer and currently in Phase II f...

(Curcumin + doxorubicin) by Immix BioPharma for Colorec...

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and cu...

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihoo...

Enzalutamide is under clinical development by Pfizer and currently in Phase II f...

(Curcumin + doxorubicin) by Immix BioPharma for Metasta...

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and cu...

Mecbotamab vedotin by BioAtla for Breast Cancer: Likeli...

Mecbotamab vedotin is under clinical development by BioAtla and currently in Pha...

(Curcumin + doxorubicin) by Immix BioPharma for Triple-...

(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and cu...

Lenvatinib mesylate by Eisai for Metastatic Biliary Tra...

Lenvatinib mesylate is under clinical development by Eisai and currently in Phas...

Opinion: STAT readers on patient advocacy, the utility ...

“The author owes the FDA an apology”: STAT readers on patient advocacy, the util...